{"url":"https://whatshealthyandwhy.com/vitamin-k2/calcium-routing","path":"/vitamin-k2/calcium-routing","alternates":{"json":"https://whatshealthyandwhy.com/api/articles/vitamin-k2/calcium-routing.json","markdown":"https://whatshealthyandwhy.com/vitamin-k2/calcium-routing.md"},"topic":{"slug":"vitamin-k2","name":"Vitamin K2","url":"https://whatshealthyandwhy.com/vitamin-k2"},"slug":"calcium-routing","order":1,"title":"Calcium routing","question":"Does vitamin K2 move calcium from arteries into bones?","answer":"Vitamin K2 may slow bone loss after menopause, and high dietary K2 is linked to fewer heart deaths, but artery protection is unproven.","description":"Without vitamin K2, calcium goes to your arteries instead of your bones — the calcium paradox explained","confidence":2,"confidenceNote":"One 244-woman RCT found less bone loss with MK-7; a 4,807-person cohort links K2 to fewer cardiac deaths; no cited trial measures artery calcification.","evidenceSummary":{"rctCount":1,"observationalCount":1,"metaAnalysisCount":0,"totalParticipants":"5,000+","replicated":false,"newestStudyYear":2017},"category":{"categoryTitle":"What's Good For You","categorySlug":"good-for-you","subcategoryName":"Supplements & Vitamins","subcategorySlug":"supplements","url":"https://whatshealthyandwhy.com/explore/good-for-you/supplements"},"actions":["Eat natto (about 1,000 mcg MK-7 per 100 g), Gouda or Brie cheese, egg yolks or dark poultry meat for vitamin K2 [2][4].","If supplementing, the 3-year trial used 180 mcg a day of MK-7, which lasts about 72 hours in the body [3][2].","If you take vitamin D3 and calcium, ask your doctor about adding K2; D3 raises demand for K2-activated proteins [2]."],"cautions":["Vitamin K is involved in blood clotting, so check with your doctor before supplementing if you take blood-thinning medication.","The heart link comes from an observational cohort where K2 came mainly from cheese, so it does not prove K2 protects arteries [1].","The bone trial enrolled healthy postmenopausal women and measured bone density and biomarkers, not fractures [3]."],"simpleText":"There is a cruel irony at the heart of calcium supplementation: many people take calcium for their bones, but without the right cofactors, a significant portion of that calcium can end up deposited in their arteries instead. This is sometimes called the calcium paradox — osteoporosis and arterial calcification occurring simultaneously in the same person [2].\n\nVitamin K2 is the nutrient that resolves this paradox. It activates proteins that direct calcium where it belongs (bones and teeth) and away from where it causes harm (arteries and soft tissue) [4].\n\nIf you take vitamin D3 and calcium, you need to know about K2. If you take D3 without K2, you should seriously consider adding it.","mediumText":"Vitamin K exists in two main forms: K1 (phylloquinone), found abundantly in green leafy vegetables, and K2 (menaquinone), found primarily in fermented foods and animal products. While K1 is well known for its role in blood clotting, K2 has a distinct and arguably more important function: it activates calcium-regulating proteins throughout the body [2].\n\nThe two key proteins that K2 activates:\n\n- Osteocalcin: Produced by osteoblasts, this protein binds calcium and incorporates it into the bone matrix. Without vitamin K2-dependent carboxylation, osteocalcin remains inactive (undercarboxylated) and cannot effectively direct calcium into bones [4].\n- Matrix Gla Protein (MGP): The most potent inhibitor of arterial calcification known. MGP must be carboxylated by vitamin K2 to function. Without adequate K2, MGP remains inactive and arteries lose their primary defense against calcium buildup [2].\n\nThis is why the calcium paradox happens. Vitamin D3 increases calcium absorption from the gut, which is beneficial. But D3 alone does not determine where that calcium goes. K2 is the routing signal. Without it, you absorb more calcium but lack the molecular machinery to put it in the right place [4].\n\nMK-4 vs MK-7 are the two most studied forms of vitamin K2. MK-4 (menaquinone-4) has a short half-life of about 1-2 hours, requiring multiple daily doses of 15-45 mg. MK-7 (menaquinone-7) has a much longer half-life of approximately 72 hours, builds up steady-state levels with a single daily dose of 100-200 mcg, and is the form used in most clinical trials on cardiovascular and bone outcomes [2]. MK-7 is the more practical choice for supplementation, though MK-4 at high doses has been used therapeutically in Japan for osteoporosis since the 1990s.\n\nFood sources of K2 are fairly specific:\n\n- Natto (fermented soybeans): By far the richest source, containing roughly 1,000 mcg of MK-7 per 100g serving. One tablespoon can provide more K2 than most supplements.\n- Gouda and Brie cheese: Contain 50-75 mcg of K2 per 100g, mostly as MK-9 and other long-chain forms.\n- Egg yolks: Contain modest amounts of MK-4 (15-30 mcg per yolk), primarily from pastured chickens.\n- Chicken liver and dark meat: Provide MK-4, though amounts vary significantly depending on the animal's diet [4].\n\nThe D3+K2 pairing is increasingly recognized as essential rather than optional. Vitamin D3 increases the production of both osteocalcin and MGP, which creates a greater demand for K2 to activate these proteins. Supplementing D3 without K2 may actually worsen the calcium paradox by producing more inactive calcium-binding proteins [2].","deepText":"The Rotterdam Study was a landmark prospective cohort study that followed 4,807 Dutch men and women over 7-10 years. Geleijnse et al. (2004) found that participants in the highest tertile of vitamin K2 intake (primarily from cheese) had a 57% reduction in cardiac mortality and a 52% reduction in severe aortic calcification compared to those in the lowest tertile [1]. Critically, vitamin K1 intake showed no such association. This was the first large-scale evidence that K1 and K2 have distinct cardiovascular roles, and it shifted research attention firmly toward K2.\n\nBeulens et al. (2013) reviewed the accumulated evidence for K2's role in human health, consolidating data from epidemiological and intervention studies [2]. They highlighted that undercarboxylated osteocalcin and MGP serve as functional biomarkers of vitamin K2 status, and that subclinical K2 deficiency — detectable only through these markers — is common even in populations with adequate K1 intake. This finding is significant because standard coagulation tests (which reflect K1 status) can appear normal while K2-dependent proteins remain inactive.\n\nThe three-year randomized controlled trial by Knapen et al. (2013) assigned 244 healthy postmenopausal women to receive either 180 mcg/day of MK-7 or placebo [3]. The MK-7 group showed significantly decreased levels of undercarboxylated osteocalcin, indicating improved calcium deposition into bone. Bone mineral density at the lumbar spine and femoral neck declined less in the MK-7 group, and bone strength indices of the femoral neck were significantly improved. The study also demonstrated decreased levels of undercarboxylated MGP, suggesting simultaneous arterial protection. This was important evidence that a single low-dose MK-7 supplement could benefit both bone and cardiovascular endpoints.\n\nThe research landscape continues to evolve. Schwalfenberg (2017) reviewed the evidence for vitamin K supplementation in conditions including osteoporosis, vascular calcification, arthritis, cancer, renal calculi, diabetes, and warfarin therapy, finding Level I and II evidence for vitamins K1 and K2 in osteoporosis and Level II evidence for vitamin K2 in preventing coronary calcification and cardiovascular disease, but insufficient evidence for diabetes, arthritis, renal calculi, and cancer, although vitamin K2 appears promising in diabetes, cancer, and osteoarthritis [4]. This suggests that K2's role in calcium metabolism may be just one facet of a broader biological function.","deepTruncated":false,"references":[{"id":"1","title":"Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: the Rotterdam Study","authors":"Geleijnse JM, Vermeer C, Grobbee DE, Schurgers LJ, Knapen MH, van der Meer IM, Hofman A, Witteman JC","year":2004,"journal":"Journal of Nutrition","pmid":"15514282","url":"https://pubmed.ncbi.nlm.nih.gov/15514282/"},{"id":"2","title":"The role of menaquinones (vitamin K2) in human health","authors":"Beulens JW, Booth SL, van den Heuvel EG, Stoecklin E, Baka A, Vermeer C","year":2013,"journal":"British Journal of Nutrition","pmid":"23590754","url":"https://pubmed.ncbi.nlm.nih.gov/23590754/"},{"id":"3","title":"Three-year low-dose menaquinone-7 supplementation helps decrease bone loss in healthy postmenopausal women","authors":"Knapen MH, Drummen NE, Smit E, Vermeer C, Theuwissen E","year":2013,"journal":"Osteoporosis International","pmid":"23525894","url":"https://pubmed.ncbi.nlm.nih.gov/23525894/"},{"id":"4","title":"Vitamins K1 and K2: The Emerging Group of Vitamins Required for Human Health","authors":"Schwalfenberg GK","year":2017,"journal":"Journal of Nutrition and Metabolism","pmid":"28698808","url":"https://pubmed.ncbi.nlm.nih.gov/28698808/"}],"wordCount":876,"source":{"path":"src/content/topics/vitamin-k2/calcium-routing.md"},"citeAs":"“Does vitamin K2 move calcium from arteries into bones?.” What's Healthy and Why. https://whatshealthyandwhy.com/vitamin-k2/calcium-routing","notice":"General information backed by peer-reviewed research, not medical advice."}